Gilead Sciences Net Tangible Assets

Gilead Sciences's net tangible assets stands at $13B as of September 2026. That compares with $21B in the prior-year period — down 40.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Gilead Sciences reported $13B in net tangible assets versus $21B a year earlier — a 40.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $21B in the prior-year period — down 40.5% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Gilead Sciences's net tangible assets evolved across reporting periods, while the comparison chart places GILD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Gilead Sciences's reading of $13B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.